nach oben

Pediatric Nephrology

Erschienen in:

21.06.2018 | Educational Review

Uric acid and progression of chronic kidney disease

verfasst von: Donald J. Weaver Jr

Erschienen in: Pediatric Nephrology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

The association between serum uric acid levels and human disease has garnered intense interest over the last decade including chronic kidney disease. Animal studies have provided evidence for a potential mechanistic role of uric acid in promoting progression of chronic kidney disease. Epidemiologic studies have also suggested an association between elevated serum uric acid levels and worsening renal function in the general population as well as in patients with chronic kidney disease. However, there is currently insufficient evidence to recommend the use of uric acid-lowering therapy to delay progression of chronic kidney disease in this patient population. Adequately powered, randomized, placebo-controlled trials are required to more precisely evaluate the risk and benefits of uric acid-lowering therapy in pediatric patients.

Fathallah-Shaykh SA, Cramer MT (2014) Uric acid and the kidney. Pediatr Nephrol 29:999–1008CrossRefPubMed

Mallat SG, Kattar SA, Tanios BY, Jurjus A (2016) Hyperuricemia, hypertension, and chronic kidney disease: an emerging association. Curr Hypertens Rep 18:74CrossRefPubMed

Li X, Meng X, Timofeeva M, Tzoulaki I, Tsilidis KK, Ioannidis JP, Campbell H, Theodoratou E (2017) Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomized controlled trials, and Mendelian randomization studies. BMJ 357:2376–2400CrossRef

Wright AF, Rudan I, Hastie ND, Campbell H (2010) A complexity of urate transporters. Kidney Int 78:446–452CrossRefPubMed

Wilcox WD (1996) Abnormal serum uric acid levels in children. J Pediatr 128:731–741CrossRefPubMed

Stiburkova B, Bleyer AJ (2012) Changes in serum urate and urate excretion with age. Adv Chronic Kidney Dis. 19:372–376CrossRefPubMed

Tsukahara H, Hiraoka M, Hori C, Tsuchida S, Uchida H, Fujisawa K, Konishi Y, Sudo M (1996) Urinary uric acid excretion in term and premature infants. J Paediatr Child. Health. 32:330–332CrossRefPubMed

Luciano R, Shashaj B, Spreghini DFA, Rustico C, Wietrzykowska Sforza R, Morino GS, Dallapiccola B, Manco M (2017) Percentiles of serum uric acid and cardiometabolic abnormalities in obese Italian children and adolescents. Italian J Pediatr 43:3–7CrossRef

Tam HK, Kelly AS, Fox CK, Nathan BM, Johnson LA (2016) Weight loss mediated reduction in xanthine oxidase activity and uric acid clearance in adolescents with severe obesity. Child Obes. 12:286–291CrossRefPubMedPubMedCentral

10.

Ricotti R, Genoni G, Giglione E, Monzani A, Nugnes M, Zanetta S, Castagno M, Marolda A, Bellomo G, Bona G, Bellone S, Prodam F (2018) High-normal estimated glomerular filtration rate and hyperuricemia positively correlate with metabolic impairment in pediatric obese patients. PLOS One 13:e0193755CrossRefPubMedPubMedCentral

11.

Venkat-Raman G, Gast C, Marinaki A, Fairbanks L (2016) From juvenile hyperuricaemia to dysfunctional uromodulin: an ongoing metamorphosis. Pediatr Nephrol 31:2035–2042CrossRefPubMed

12.

Mazzali M, Hughes J, Kim Y-G, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ (2001) Elevated uric acid increases blood pressure in the rat by a novel crystal independent mechanism. Hypertension 38:1101–1106CrossRefPubMed

13.

Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ (2002) A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888–2897CrossRefPubMed

14.

Mazzali M, Kanelis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ (2002) Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. American J Physiol-Renal Physiol 282:F991–F997CrossRef

15.

Diwan V, Mistry A, Gobe G, Brown L (2013) Adenine-induced chronic kidney and cardiovascular damage in rats. J Pharm Toxicol Methods 68:197–207CrossRef

16.

Correa-Cost M, Braga TT, Semedo P, Hayashida CY, Bechara LR, Elias RM, Barreto CR, Silva-Cunha C, Hyane MI, Gonçalves GM, Brum PC, Fujihara C, Zatz R, Pacheco-Silva A, Zamboni DS, Camara NO (2011) Pivotal role of toll-like receptors 2 and 4, its adaptor molecule, MyD88, and inflammasone complex in experimental tubule-interstitial nephritis. PLoS ONE 6:e29004CrossRef

17.

Han HJ, Lim MJ, Lee YJ, Lee JH, Yang IS, Taub M (2007) Uric acid inhibitors renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NK-κB. Am J Physiol-Renal Physiol 292:F373–F381CrossRefPubMed

18.

Sanchez-Lozada LG, Tapi E, Soto V (2008) Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 23:1179–1185CrossRefPubMed

19.

Sanchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Wessale JL, Zhao L, Johnson RJ (2008) Effect of febuxostat on the progression of renal disease in the 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol 103:69–78CrossRef

20.

Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ (2003) Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen activated protein kinase and cyclooxygenase-2. Hypertens 41:1287–1293CrossRef

21.

Hwang SJ, Lee KH, Jang HH, Lee SR, Woo JS, Lee HJ, Jung KH, Kim W (2014) Febuxostat contributes to improvement of endothelial dysfunction in an experimental model of streptozocin-induced diabetic rats. Int J Cardiol 171:e110–e112CrossRefPubMed

22.

Sanchez-Lozada LG, Tapia E, Lopez-Molina R, Nepomuceno T, Soto V, Avila-Casado C, Nakagawa T, Johnson RJ, Herrera-Acosta J, Franco M (2007) Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol Renal Physiol 292:1238–1244CrossRef

23.

Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26:269–275CrossRefPubMed

24.

Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112:1776–1784CrossRefPubMedPubMedCentral

25.

Ryu ES, Kim MJ, Shin HS, Jang YH, Choi HS, Jo I, Johnson RJ, Kang DH (2013) Uric acid induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol 304:F471–F480CrossRefPubMed

26.

Carew RM, Wang B, Kantharidis P (2012) The role of EMT in renal fibrosis. Cell and Tissue Res 347:103–116CrossRef

27.

Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, Kestenbaum B, Carney JK, Fried LF (2007) Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 50:239–247CrossRefPubMed

28.

Odden MC, Amadu A-R, Smit E, Lo L, Peralta CA (2014) Uric acid levels, kidney function, and the cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988–1994 and 1999–2002. Am J Kidney Dis 64:550–557CrossRefPubMedPubMedCentral

29.

De W, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS (2008) Uric acid and incident kidney disease in the community. J Am Soc Nephrol 19:1204–1211CrossRef

30.

Domrongkitchaiporn S, Sritara P, Kitiyakara C, Stitchantrakul W, Krittaphol V, Lolekha P, Cheepudomwit S, Yipintsoi T (2005) Risk factors for development of decreased kidney function in a Southeast Asian population: A 12-year cohort study. J Am Soc Nephrol 16:791–799CrossRefPubMed

31.

De Cosmo S, Viazzi F, Pacilli A, Giorda C, Ceriello A, Gentile S, Russo G, Rossi MC, Nicolucci A, Guida P, Feig D, Johnson RJ, Pontremoli R, AMD-Annals Study Group (2015) Serum uric acid and risk of ckd in type 2 diabetes. Clin. J Am Soc Nephrol. 10:1921–1929CrossRefPubMedPubMedCentral

32.

Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R (2008) Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 19:2407–2413CrossRefPubMedPubMedCentral

33.

Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS (2009) Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 169:342–350CrossRefPubMedPubMedCentral

34.

Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS (2018) Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis 71:362–370CrossRefPubMed

35.

Liu WC, Hung CC, Chen SC, Yeh SM, Lin MY, Chiu YW, Kuo MC, Chang JM, Hwang SJ, Chen HC (2012) Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin. J Am Soc Nephrol 7:541–548CrossRefPubMed

36.

Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, Collins AJ, Levey AS, Menon V (2009) Uric acid and long-term outcomes in CKD. Am J Kidney Dis 53:796–803CrossRefPubMedPubMedCentral

37.

Sturm G, Kollertis B, Neyer U, Ritz E, Kronenberg F, MMKD Study Group (2008) Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol 43:347–352CrossRefPubMed

38.

Kalil RS, Carpenter MA, Ivanova A, Gravens-Mueller L, John AA, Weir MR, Pesavento T, Bostom AG, Pfeffer MA, Hunsicker LG (2017) Impact of hyperuricemia on long-term outcomes of kidney transplantation: analysis of the FAVORIT study. Am J Kidney Dis 70:762–769CrossRefPubMed

39.

Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47:51–59CrossRefPubMed

40.

Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R, Covic A (2007) Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal function. Int Urol Nephrol 39:1227–1233CrossRefPubMed

41.

Malaguarnera M, Vacante N, Russo C, Dipasquale G, Gargante MP, Motta M (2009) A single dose of rasburicase in elderly patients with hyperuricemia reduces serum uric acid levels and improves renal function. Expert Opin Pharmacother 10:737–742CrossRefPubMed

42.

Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk Clin. J Am Soc Nephrol 22:1382–1389

43.

Momeni A, Shahidi S, Seirfian S, Taheri S, Kheiri S (2011) Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis 4:128–132

44.

Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L (2011) Renal function in gout: long term treatment effects of febuxostat. J Clin Rheumatol 17:7–13CrossRefPubMed

45.

Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H, Yang Q, Johnson RJ, Yu X (2010) Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res 235:153–160

46.

Santosh Pai BH, Swarnalatha G, Dakshinamurty KV RR (2013) Allopurinol for prevention of progressive kidney disease with hyperuricemia. Indian J Nephrol 23:280–286CrossRef

47.

Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, Pérez de Jose A, Cedeño S, Linares T, Luño J (2015) Allopurinol and progression of chronic kidney disease and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis. 65:543–549CrossRefPubMed

48.

Sircar D, Chatterjee S, Waikom R, Golay V, Raychaudhury A, Chatterjee S2 Pandey R (2015) Efficacy of Febuxostat for slowing the GFR decline in patients with CKD and symptomatic hyperuricemia: a 6 month, double blind, randomized, placebo controlled trial. Am J Kidney Dis 66:945–950.

49.

Chou HW, Chiu HT, Tsai CW, Ting IW, Yeh HC, Huang HC, Kuo CC, CMUH Kidney Research Group (2017) Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13 year inception cohort study. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfx313

50.

Tallat KM, El-Sheikh AR (2007) The effect of mild hyperuricemia on urinary transforming growth factor β and the progression of chronic kidney disease. Am J Nephrol 27:435–440CrossRef

51.

Sezer S, Karakan S, Atesagaoglu B, FNO A (2014) Allopurinol reduces cardiovascular risks and improves renal function in pre-dialysis chronic kidney disease patients with hyperuricemia. Saudi J Kidney Dis Transpl 25:316–320CrossRefPubMed

52.

Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, de Zoysa JR, Fassett RG, Faull R, Harris DC, Hawley CM, Kanellis J, Palmer SC, Perkovic V, Pascoe EM, Rangan GK, Walker RJ, Walters G, Johnson DW (2014) Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant 29:406–413CrossRefPubMed

53.

Kanji T, Gandhi M, Clase MC (2015) Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis BMC Nephrol 16:58–64PubMed

54.

Sampson AL, Singer RF, Walters GD (2017) Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009460.pub2

55.

Miao Y, Ottenbros SA, Lverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D, Lambers Heerspink HJ (2011) Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 58:2–7CrossRefPubMed

56.

Hosoya T, Kimura K, Itoh S, Inaba M, Uchida S, Tomino Y, Makino H, Matsuo S, Yamamoto T, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H (2014) The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. Trials. 15:26CrossRefPubMedPubMedCentral

57.

Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 300:924–932CrossRefPubMedPubMedCentral

58.

Soletsky B, Feig D (2012) Uric acid reduction rectifies prehypertension in obese adolescents. Hypertens 60:1148–1156CrossRef

59.

Kubota M, Nagai A, Tang L, Tokuda M (2011) Investigation on hyperuricemia in children with obesity or various pediatric disorders. Nucleosides Nucleotides Nuclei Acids. 30:1051–1059CrossRef

60.

Reschke LD, Miller ER, Fadrowski JJ, Loeffler LF, Holmes KW, Appel LJ, Brady TM (2015) Elevated uric acid and obesity-related cardiovascular disease risk factors among hypertensive youth. Pediatr Nephrol. 30:2169–2176CrossRefPubMedPubMedCentral

61.

Rodenbach KE, Schneider MF, Furth SL, Moxey-Mims MM, Mitsnefes MM, Weaver DJ, Warady BA, Schwartz GJ (2015) Hyperuricemia and progression of CKD in children and adolescents: the chronic kidney disease in children (CKiD) cohort study. Am J Kidney Dis 66:984–992CrossRefPubMedPubMedCentral

62.

Fidan C, Kantar A, Baskin E, Gülleroğlu K, Akdur A, Moray G, Haberal M (2015) Effects of hyperuricemia on renal function in pediatric renal transplant recipients. Exp Clin Transplant 13(Suppl 1):247–250PubMed

Titel: Uric acid and progression of chronic kidney disease
verfasst von: Donald J. Weaver Jr
Publikationsdatum: 21.06.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Nephrology / Ausgabe 5/2019
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-018-3979-2

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Uric acid and progression of chronic kidney disease

Abstract

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Predictors of grade 3–5 vesicoureteral reflux in infants ≤ 2 months of age with pyelonephritis

Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study)

A breakthrough in readthrough? Could geneticin lead the way to effective treatment for cystinosis nonsense mutations?

Chronic kidney disease following twin-to-twin transfusion syndrome—long-term outcomes

Persistent fever in a pediatric renal transplant patient: Answers

Dangerous hyperkalemia in a newborn: Answers

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie